AST-120

ApprovedSmall molecule

OOcera Therapeutics

AST-120 is one of 161 small molecule programs targeting Kidney Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseActive, not recruiting

EncephalopathyActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

PouchitisActive, not recruiting

Kidney DiseaseApproved

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

Irritable Bowel SyndromePhase 2

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

PouchitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

AST-120

OOcera Therapeutics

Approved

3 2

Aranesp

Amgen

Preclinical

40 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Uloric

Takeda

Preclinical

3 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Lorelco

Sanofi

Preclinical

1 8

Sovaldi

Gilead

Preclinical

1 9

Activase

Flomax

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Kidney Disease

NCT07182422

Clinical

Trials by Indication[1]

Chronic Kidney Disease3 trials

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT00500682·1,020 enrolled

Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.

Completed·—·Phase 4·NCT01681303·51 enrolled

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT00501046·1,015 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Terminated·OOcera Therapeutics·Phase 2·NCT00587275·4 enrolled

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Completed·OOcera Therapeutics·Phase 3·NCT00321412·191 enrolled

Encephalopathy2 trials

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

Completed·OOcera Therapeutics·Phase 2·NCT00558038·40 enrolled

AST-120 Used to Treat Mild Hepatic Encephalopathy

Completed·OOcera Therapeutics·Phase 2·NCT00867698·148 enrolled

Pouchitis2 trials

Safety and Efficacy of AST-120 in the Treatment of Pouchitis

Completed·OOcera Therapeutics·Phase 2·NCT00583076·19 enrolled

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Terminated·OOcera Therapeutics·Phase 2·NCT00583531·2 enrolled

Irritable Bowel Syndrome1 trial

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Completed·OOcera Therapeutics·Phase 2·NCT00583128·117 enrolled

4 more indications

Kidney Disease1 trial

AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

Recruiting·—·Phase 4·NCT07182422·100 enrolled

Interaction1 trial

Drug-Drug Interaction Study of TRK-100STP

Completed· Astellas logo

Astellas·Phase 1·NCT00719758·24 enrolled

Pruritus1 trial

AST-120 in Hemodialysis Patients With Uremic Pruritus

Completed·CConmed Pharmaceutical & Bio-Medical Corporation·Phase 4·NCT04639674·100 enrolled

Disease Progression1 trial

Kremezin Study Against Renal Disease Progression in Korea

Completed·SSeoul National University Hospital·Phase 4·NCT00860431·578 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for AST-120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AST-120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AST-120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ocera Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOcera Therapeutics

AST-120

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chronic Kidney Disease3 trials

Safety and Efficacy2 trials

Encephalopathy2 trials

Pouchitis2 trials

Irritable Bowel Syndrome1 trial

Kidney Disease1 trial

Interaction1 trial

Pruritus1 trial

Disease Progression1 trial

References

Drug Info

Quick Facts

Related News